Patent Application
20230313272
The present invention relates to methods of determining the integrity and quality of RNA samples.
RNA is extremely susceptible to degradation and RNase is ubiquitous in the environment. However, isolation of intact RNA is essential for many techniques used, for example, in gene expression analysis.
The most common method used to assess the integrity of total RNA is agarose or acrylamide electrophoresis. General information about RNA integrity can be obtained by observing the staining intensity of the major ribosomal RNA (rRNA) bands and any degradation products. For eukaryotic rRNA, a 28S:18S ratio of 2:1 is generally representative of intact RNA, but it is not always accurate. However, while the cost of analyzing RNA by gel electrophoresis is relatively low, the analysis requires a significant amount of handling and hands on time. Furthermore, this method does not reliably give accurate results on the integrity of the RNA sample.
An alternative method uses UV absorbance to measure RNA concentration and purity. Absorbance at 260 nm is used to measure the amount of nucleic acid in a sample. However this method cannot determine the integrity of RNA in a sample because all RNA, whether intact or degraded, contributes to the absorbance at 260 nm and therefore intact RNA cannot be distinguished from degraded RNA.
A third alternative, the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) uses microfluidics to analyze RNA using sample-specific chips (see, for example, U.S. Pat. No. 8,346,486). The 2100 Bioanalyzer uses kits that are specific for the sample of interest; for example, kits are available for small RNA and microRNA as well as total RNA and mRNA. The 2100 Bioanalyzer is able to measure RNA integrity which is displayed as an RNA Integrity Number (RIN). To determine the RIN, the instrument uses a proprietary algorithm that takes into account the entire electrophoretic trace of the RNA, not just the 28S and 18S rRNAs. However, the 2100 Bioanalyzer has several disadvantages including: time-consuming sample preparation with considerable hands-on time, lack of sample flexibility due to the requirement of sample-specific chips, and the costs of the instrument, reagents and chips may be prohibitive to some labs.
Other methods similar to the 2100 Bioanalyzer RIN analysis have been developed for obtaining a metric for RNA integrity or quality. For example, a microfluidic assay has been developed using the Perkin Elmer LabChip® GX Touch microfluidics platform (PerkinElmer, Inc., Waltham, MA) to analyze RNA by electrophoretic separation on microfluidic sipper chips. The resulting electropherogram is used to calculate a RNA Quality Score (RQS) which correlates with Agilent's RIN and follows the same 0 to 10 scale rating.
Yet another method for determining RNA quality uses a direct functional RT-PCR based test to assess human or mouse RNA for its ability to produce full-length cDNA. This method uses two sets of primers to amplify the 5′ and 3′ end fragments of a long mRNA for a reference gene. The resulting amplification products are separated by electrophoresis and the ratio of the 3′ and 5′ amplification products is obtained. A 3′:5′ ratio of 1 indicates the RNA is intact, while a 3′:5′ ratio of >3 indicates degraded RNA. The disadvantages of this method include a time-consuming work flow and the sample of interest must contain the gene to which the primers bind.
In addition, the standard methods described above for assessing RNA quality and integrity are insufficient for RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissue samples due to the extensive degradation and modification of the RNA from long-term storage and fixation methods.
Thus, there is a need for a faster, easier method for measuring RNA sample quality, including RNA isolated from FFPE samples. The RNA quality method described herein is a reliable, easy to use method for determining whether the RNA in a sample has degraded.
The present disclosure provides a method of determining the extent of degradation of RNA in a sample, expressed as an RNA quality value, the method comprising:
The present disclosure provides a method of determining the extent of degradation of RNA in a sample, expressed as an RNA quality value, the method comprising:
In certain embodiments of the methods provided herein, the large and/or structured RNA is rRNA, tRNA or mRNA. In certain embodiments, the small RNA comprises 200 nucleotides (nt) or fewer. In certain embodiments, the small RNA is selected from miRNA, siRNA, fragments of mRNA, fragments of tRNA, or fragments of rRNA. In preferred embodiments, the large and/or structured RNA is indicative of intact RNA and the small RNA is indicative of degraded RNA.
In certain embodiments, the first nucleic acid binding dye and the second nucleic acid binding dye are added to the sample at the same time. In certain embodiments, the first nucleic acid binding dye and the second nucleic acid binding dye are added to the sample separately or sequentially. In certain preferred embodiments, a dye solution comprising the first nucleic acid binding dye and the second nucleic acid binding dye is prepared and is used to administer the first nucleic acid binding dye and the second nucleic acid binding dye to the sample.
In certain embodiments of the methods provided herein, the first nucleic acid binding dye is a cyanine, a xanthene, a coumarin, a pyrene, an indole, a benzofuran or a borapolyazaindacene. In certain embodiments, the second nucleic acid binding dye is a cyanine, a xanthene, a coumarin, a pyrene, an indole, a benzofuran or a borapolyazaindacene. In certain preferred embodiments, the first nucleic acid binding dye is a cyanine. In certain preferred embodiments, the first nucleic acid binding dye is a compound of Formula (III). In certain preferred embodiments, the compound of Formula (III) is selected from a compound described in Table 1. In certain more preferred embodiments, the first nucleic acid binding dye is Compound 16, Compound 17, Compound 23, Compound 24, Compound 29, Compound 30, Compound 45, Compound 46, Compound 47, Compound 52, Compound 53, Compound 59, Compound 60 or Compound 61.
In certain embodiments of the methods provided herein, the second nucleic acid binding dye is a cyanine. In certain preferred embodiments, the second nucleic acid binding dye is a compound of Formula (IV). In certain preferred embodiments, the compound of Formula (IV) is selected from a compound described in Table 2. In certain more preferred embodiments, the second nucleic acid binding dye is Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14 or Compound 15.
In certain embodiments of the methods provided herein, the first nucleic acid binding dye is Compound 16, Compound 17, Compound 23, Compound 24, Compound 29, Compound 30, Compound 45, Compound 46, Compound 47, Compound 52, Compound 53, Compound 59, Compound 60 or Compound 61, and the second nucleic acid binding dye is Compound 1, Compound 2, Compound 3, Compound 4, Compound 7, Compound 9, Compound 10, Compound 12, Compound 13, Compound 14 or Compound 15.
In certain embodiments of the methods provided herein, the second nucleic acid binding dye has a RNA/DNA fluorescence enhancement ratio of ≥7, ≥10 or ≥20. In certain embodiments of the methods provided herein, the first nucleic acid binding dye has a single-stranded RNA fluorescence enhancement of ≥30%.
In certain embodiments of the methods provided herein, the detecting step is performed by fluorometry.
In certain embodiments, the methods provided herein further comprise:
In certain embodiments, the methods provided herein further comprise determining the extent of degradation of the RNA present in the illuminated sample mixture based on comparison of the detectable fluorescent signal in the illuminated sample mixture with a ratio of the fluorescent signal of the second standard solution and the fluorescent signal of the first standard solution. In certain preferred embodiments, the step of determining the extent of degradation of the RNA present in the illuminated sample mixture is calculated by Formula (I). In certain more preferred embodiments, the step of determining the extent of degradation of the RNA present in the illuminated sample mixture is calculated by Formula (II).
In certain embodiments, the present disclosure provides a kit comprising:
In certain embodiments, the present disclosure provides a kit comprising:
In certain embodiments of the kits provided herein, the kits further comprise:
In certain embodiments, the present disclosure provides an RNA quality staining solution comprising:
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying drawings. While the invention will be described in conjunction with the illustrated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the invention as defined by the appended claims.
To more clearly and concisely describe and point out the subject matter of the present disclosure, the following definitions are provided for specific terms, which are used in the following description and the appended claims. Throughout the specification, exemplification of specific terms should be considered as non-limiting examples.
As used in this specification, the words “a” or “an” mean at least one, unless specifically stated otherwise. In this specification, the use of the singular includes the plural unless specifically stated otherwise. For example, but not as a limitation, “a nucleic acid” means that more than one nucleic acid can be present; for example, one or more copies of a particular nucleic acid species, as well as two or more different species of nucleic acid. The term “and/or” means that the terms before and after the slash can be taken together or separately. For illustration purposes, but not as a limitation, “X and/or Y” can mean “X or Y” or “X and Y”.
It will be appreciated that there is an implied “about” prior to the temperatures, concentrations, times, etc. discussed in the present disclosure, such that slight and insubstantial deviations are within the scope of the present teachings herein. Also, the use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory only and are not restrictive of the teachings.
Unless specifically noted in the specification, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of” or “consisting essentially of” the recited components; embodiments in the specification that recite “consisting of” various components are also contemplated as “comprising” or “consisting essentially of” the recited components; and embodiments in the specification that recite “consisting essentially of” various components are also contemplated as “consisting of” or “comprising” the recited components (this interchangeability does not apply to the use of these terms in the claims).
The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed terms preceding the term. For example, “A, B, C, or combinations thereof” is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, ACB, CBA, BCA, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the desired subject matter in any way. All literature cited in the specification, including but not limited to, patents, patent applications, articles, books and treatises are expressly incorporated by reference in their entirety for any purpose. In the event that any of the incorporated literature contradicts any term defined in this specification, this specification controls. While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.
As used herein, “about” refers to a value that is 10% more or less than a stated value, gives results functionally equivalent to the stated value, or rounds to the stated value.
As used herein, colors and color channels such as near infrared, red, orange, yellow, green, cyan, blue, and violet have their ordinary and customary meaning in the arts of fluorescence detection in molecular and cell biology, including fluorescence microscopy and flow cytometry. Exemplary ranges for the colors and color channels are as follows: about 380 nm to about 435 or 440 nm for violet, about 435 or 440 nm to about 485 nm or about 435 or 440 nm to about 500 nm for blue, about 485 to 500 nm or about 500 nm to about 520 nm for cyan, about 500 nm or 520 nm to about 560 nm or about 500 nm or 520 nm to about 565 nm for green, about 560 or 565 nm to about 590 nm or about 560 or 565 nm to about 600 nm for yellow, about 590 nm or 600 nm to about 625 nm or about 590 nm or 600 nm to about 650 nm for orange, about 625 nm or 650 nm to about 700 nm or about 625 nm or 650 nm to about 740 nm for red, and about 700 nm or 740 nm to about 1000 nm or about 700 nm or 740 nm to about 2000 nm for near infrared.
As used herein, the term “kit” refers to a packaged set of related components, such as one or more compounds or compositions and one or more related materials such as solvents, solutions, buffers, instructions, desiccants, or cells.
“Substituted” as used herein refers to a molecule wherein one or more hydrogen atoms are replaced with one or more non-hydrogen atoms, functional groups or moieties. By example, an unsubstituted nitrogen is —NH2, while a substituted nitrogen is —NHCH3. Exemplary substituents include but are not limited to halogen, e.g., fluorine and chlorine, (C1-C8) alkyl, sulfate, sulfonate, sulfone, amino, ammonium, amido, nitrile, nitro, lower alkoxy, phenoxy, aromatic, phenyl, polycyclic aromatic, heterocycle, water-solubilizing group, linkage, and linking moiety.
A dashed line projecting from a substituent, such as:
indicates the point of attachment to the base molecule. For a fused ring, dashed lines indicate portions of the base molecule where the fused ring is attached, such as:
wherein the full molecule could have the structure:
Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.
It is understood that in all substituted groups defined herein, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, which is further substituted by a substituted aryl group etc.) are not intended for inclusion herein. In such cases, the maximum number of such substitutions is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to-substituted aryl-(substituted aryl)-substituted aryl.
Similarly, it is understood that the definitions provided herein are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.
The compounds disclosed herein may exist in unsolvated forms as well as solvated forms, including hydrated forms. These compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses described herein and are intended to be within the scope of the present disclosure. The compounds disclosed herein may possess asymmetric carbon atoms (i.e., chiral centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers of the compounds described herein are within the scope of the present disclosure. The compounds described herein may be prepared as a single isomer or as a mixture of isomers.
Where substituent groups are specified by their conventional chemical formulae and are written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g., —CH2O— is intended to also recite —OCH2—.
It will be understood that the chemical structures that are used to define the compounds disclosed herein are each representations of one of the possible resonance structures by which each given structure can be represented. Further, it will be understood that by definition, resonance structures are merely a graphical representation used by those of skill in the art to represent electron delocalization, and that the present disclosure is not limited in any way by showing one particular resonance structure for any given structure.
Where a disclosed compound includes a conjugated ring system, resonance stabilization may permit a formal electronic charge to be distributed over the entire molecule. While a particular charge may be depicted as localized on a particular ring system, or a particular heteroatom, it is commonly understood that a comparable resonance structure can be drawn in which the charge may be formally localized on an alternative portion of the compound.
“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms, e.g. 1, 2, 3, 4, 5 or 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3—), ethyl (CH3CH2—), n-propyl (CH3CH2CH2—), isopropyl ((CH3)2CH—), n-butyl (CH3CH2CH2CH2—), isobutyl ((CH3)2CHCH2—), sec-butyl ((CH3)(CH3CH2)CH—), t-butyl ((CH3)3C—), n-pentyl (CH3CH2CH2CH2CH2—), and neopentyl ((CH3)3CCH2—).
“Alkoxy” refers to the group —O-alkyl wherein alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
“Aryl” or “Ar” refers to a monovalent aromatic carboxylic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is at an aromatic carbon atom. Preferred aryl groups include phenyl and naphthyl.
“Alkenyl” refers to alkenyl groups having from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1 to 2 sites of alkenyl unsaturation. Such groups are exemplified, for example, by vinyl, allyl, but-3-en-1-yl, and propenyl.
“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, substituted alkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—, alkynyl-C(O)—, substituted alkynyl-C(O)—, cycloalkyl-C(O)—, substituted cycloalkyl-C(O)—, cycloalkenyl-C(O)—, substituted cycloalkenyl-C(O)—, aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—, substituted heteroaryl-C(O)—, heterocyclic-C(O)—, and substituted heterocyclic-C(O)—, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein. Acyl includes the “acetyl” group CH3C(O)—.
“Amino” refers to the group —NH2.
“Carbonyl” refers to the divalent group —C(O)— which is equivalent to —C(═O)—.
“Carboxyl” or “carboxy” refers to —COOH or salts thereof.
“Cycloalkyl” refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including fused, bridged, and spiro ring systems. Examples of suitable cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl.
“H” indicates hydrogen.
“Halo” or “halogen” refers to fluoro, chloro, bromo and iodo.
“Hydroxy” or “hydroxyl” refers to the group —OH.
“Heteroaryl” refers to an aromatic group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridinyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl) wherein the condensed rings may or may not be aromatic and/or contain a heteroatom provided that the point of attachment is through an atom of the aromatic heteroaryl group. In one embodiment, the nitrogen and/or the sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N-oxide (N→O), sulfinyl, or sulfonyl moieties. Preferred heteroaryls include pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl.
“Heterocycle” or “heterocyclic” or “heterocycloalkyl” or “heterocyclyl” refers to a saturated or unsaturated group having a single ring or multiple condensed rings, including fused bridged and spiro ring systems, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more the rings can be cycloalkyl, aryl or heteroaryl provided that the point of attachment is through the non-aromatic ring. In one embodiment, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, sulfinyl, or sulfonyl moieties.
Examples of heterocycle and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine, and tetrahydrofuranyl.
“Sulfo” refers to the groups —SO3H or —SO3—.
“Sulfonyl” refers to the divalent group —S(O)2—.
“Thiol” refers to the group —SH.
“Alkylthio” refers to the group —S-alkyl wherein alkyl is as defined herein.
The term “assay” as used herein refers to an investigative analytic procedure for qualitatively assessing or quantitatively measuring the presence, amount or functional activity of a target entity. The methods of the present disclosure can be used in assays to determine the integrity and/or quality of RNA in a sample.
The term “detectable response” as used herein refers to an occurrence of or a change in, a signal that is directly or indirectly detectable either by observation or by instrumentation. Typically, the detectable response is an optical response resulting in a change in the wavelength distribution patterns or intensity of absorbance or fluorescence or a change in light scatter, fluorescence lifetime, fluorescence polarization, or a combination of the above parameters.
The term “dye” as used herein refers to a compound that emits light to produce an observable detectable signal.
As used herein, the term “fluorophore” or “fluorogenic” refers to a compound or a composition that demonstrates a change in fluorescence upon binding to a biological compound or analyte of interest and/or upon cleavage by an enzyme. The fluorophores of the present disclosure may be substituted to alter the solubility, spectral properties or physical properties of the fluorophore.
As used herein, “large and/or structured RNA” includes large-sized RNA molecules and RNA molecules with secondary and/or tertiary structure. Exemplary large and/or structured RNA molecules include, but are not limited to, mRNA, rRNA and tRNA. The term “large and/or structured RNA” also includes intact RNA.
As used herein, “small RNA” includes small-sized RNA and RNA fragments. Exemplary small RNA molecules include, but are not limited to, miRNA, siRNA, mRNA fragments, rRNA fragments and tRNA fragments. The term “small RNA” also includes degraded RNA.
As used herein, “a pharmaceutically acceptable salt” or “a biologically compatible salt” is a counterion that is not toxic as used, and does not have a substantially deleterious effect on biomolecules. Examples of such salts include, among others, K+, Na+, Cs+, Li+, Ca2+, Mg2+, Cl−, AcO−, and alkylammonium or alkoxyammonium salts.
“Water-solubilizing group” means a substituent which increases the solubility of the compounds of the invention in aqueous solution. Exemplary water-solubilizing groups include but are not limited to quaternary amine, sulfate, sulfonate, carboxylate, phosphonate, phosphate, polyether, polyhydroxyl, and boronate.
Methods of Determining RNA Integrity and Quality & Calculation of an RNA Integrity Score (“IQ Score”):
The present disclosure provides methods, compositions and kits for determining the quality and/or integrity of RNA in a sample. The present disclosure provides reliable, easy to use methods for determining whether the RNA in a sample has degraded. These methods can be performed in 5 to 10 minutes using a fluorometer or microplate reader. Once such fluorometer that can be used in the methods of the present disclosure is a QUBIT™ Fluorometer (Thermo Fisher Scientific, Waltham, MA). The methods of the current disclosure provide the flexibility to run single samples or multiple samples. The end result, a measurement of RNA quality and/or integrity, herein termed an RNA “Quality Score” or “IQ Score”, can be relied upon independent of analyst, instrument and time of analysis.
The present disclosure provides simple, easy-to-use fluorescence-based fluorometric methods and/or assays in which the ratio of the fluorescence of two nucleic acid binding dyes reliably indicates the extent of degradation of RNA in a sample. The methods require little hands-on time and are performed in a short amount of time, for example, less than 10 min. The methods can be used to analyze a single sample or multiple samples and are able to use starting materials containing a low concentration of RNA (see
Size distributions of RNA polymers are a measure of the integrity and thus the quality of the RNA sample. The integrity of the RNA in the sample is significantly affected by contamination by RNA degrading enzymes (e.g., RNases) or mechanical shearing forces due to improper handling. A shift in length of the RNA polymer from long to short is observed when degradation has occurred.
The quality of an RNA molecule can be understood as a measure of its integrity. For example, an RNA sample will exhibit a high degree of integrity if its molecules have survived extraction from cells or tissues as a whole without suffering degradation or breakage due to shearing forces. A measure of the integrity can indicate, for example, to what extent the sample exhibits signs of degradation or shearing.
Certain embodiments of the present disclosure provide for ratiometric, fluorescence-based methods to determine the quality and/or integrity of RNA samples. The methods and resulting quality score (herein referred to as a “Quality Score” or “IQ Score”) are independent of the source and type of the sample, e.g., independent of the biological species, the conditions of the cells, the types of tissues or organs and organisms involved, as well as the concentrations of the RNA in the sample and the methods by which they were prepared.
The methods for determining RNA integrity and/or quality described herein use a combination of two spectrally distinct fluorogenic nucleic acid binding dyes, a first nucleic acid binding dye that selectively binds to small RNA, such as miRNA or small RNA fragments, and a second nucleic acid binding dye that selectively binds to large and/or structured RNA, such as mRNA, tRNA and rRNA. In the methods of the present disclosure, the amount of small RNA present in the sample is indicative of degraded RNA and the amount of large and/or structured RNA is indicative of intact RNA. The methods of the present disclosure provide a ratiometric determination of the quality and/or integrity of RNA that utilizes the ratio of the fluorescence intensity of the emission of the first nucleic acid binding dye to the fluorescence intensity of the emission of the second nucleic acid binding dye as a measure of the size ratio of the RNA sample, which in turn is indicative of the extent of RNA degradation and is independent of RNA concentration.
In certain embodiments, the methods of the present disclosure provide a determination of the relationship of the intensity of the fluorescence emission of the first nucleic acid binding dye to the intensity of the fluorescence emission of the second nucleic acid binding dye as a measure of the size of the RNA present in the sample, which in turn is indicative of the extent of RNA degradation in the sample.
In certain embodiments, a method is provided for determining the extent of degradation of RNA in a sample, wherein the extent of RNA degradation is expressed as an RNA quality score, the method comprising:
The present disclosure provides a method of determining the extent of degradation of RNA in a sample, expressed as an RNA quality value, the method comprising:
This method utilizes two different nucleic acid binding dyes, each of which selectively binds different nucleic acids. In the methods provided herein, the two dyes can be combined in the same solution and added to the RNA sample simultaneously, or each dye can be in a separate solution and added to the RNA sample sequentially or simultaneously. In certain preferred embodiments provided herein, the first nucleic acid binding dye is selective for small RNAs and optionally, double-stranded DNA (dsDNA), but not larger RNA, and is excited at 500 nm and emits at 515 nm (e.g., the green emission channel of a fluorometer) and the second nucleic acid binding dye is selective for large and/or structured RNA, and is excited at 648 nm and emits at 666 nm (e.g., the red emission channel of a fluorometer). By combining these two dyes in the same method, a size profile of the RNA is obtained, with the green emission channel representative of the amount of smaller RNA present in the sample, and the red channel representative of the large, intact RNA present in the sample. With some manipulation of the data using the equation of Formula (I), the ratio of the emission of the two channels maps onto the fraction of small RNA in the sample (see
The methods for determining RNA quality and/or integrity provided herein create a new RNA quality metric. While microfluidics-based methods, such as the 2100 Bioanalyzer, provide a RNA Integrity Number (RIN) that is calculated using a proprietary algorithm to indicate the quality of an RNA sample, such RIN values are not entirely reliable as a quality or usability metric even though they are widely used. The linearity of the methods disclosed in the present teachings, can be mapped as a quality metric, herein termed the RNA Integrity Score or “IQ Score” of Formula (I) or Formula (II). By dividing the ratio of the fluorescence emission signal of the first nucleic acid binding dye (in this embodiment, the green emission channel) to the fluorescence emission signal of the second nucleic acid binding dye (in this embodiment, the red emission channel), herein termed the “Green/Red Ratio” or “G/R ratio” by a constant to scale it to 10, and subtracting it from 10 to reverse the slope, the ratio becomes a scale from 10 to 0, with 10 representing 100% large and/or structured RNA, which is indicative of intact RNA, and 0 representing 100% small RNA, which is indicative of degraded RNA (see
The results presented in
The methods of the present disclosure provide a linear relationship between the ratio of the emissions of the first nucleic acid binding dye and second nucleic acid binding dye (i.e., the “G/R Ratio”) and the percent of small RNA (e.g., degraded RNA) in the sample. It was unexpectedly discovered that the RNA Quality Score or “IQ Score” correlates well with the RIN value determined from a 2100 Bioanalyzer (see
In certain embodiments of the method provided herein, three standard solutions are used to more precisely calculate the RNA Quality Score or “IQ Score”: Standard 1, which is a buffer blank to determine background fluorescence; Standard 2, which is a small (<200 nt) RNA standard to represent fully degraded samples; and Standard 3, which is a large and/or structured RNA (e.g., mRNA, rRNA, or tRNA) to represent fully intact RNA. To calculate the RNA Quality Score (IQ Score), the green/red (G/R) ratio is measured for both Standard 3 (high fluorescence emission of the second nucleic acid binding dye) and Standard 2 (high fluorescence emission of the first nucleic acid binding dye and low fluorescence emission of the second nucleic acid binding dye). This value displays the most linearity, but as a result displays the opposite trend, with small RNA having the highest number. For a quality score, the opposite trend is needed, with large RNA displaying a high quality score. Therefore, in the RNA Quality Score (IQ Score) provided herein, the ratio of the green emission signal to the red emission signal (G/R) is divided by a constant to scale it to 10 which is subtracted from 10 to reverse the slope. Thus, the ratio becomes a scale from 10 to 0, with 10 representing 100% large and/or structured RNA, which is indicative of intact RNA, and 0 representing 100% small RNA, which is indicative of degraded RNA. The calculation described above results in the equation of Formula (II), a solution-based assay derived quality score.
wherein GR2 represents the green/red ratio of Standard 2; GR3 represents the green/red ratio of Standard 3; and GRx represents the green/red ratio of the sample. When GRx is equal to GR2, the quality score is 0 (i.e., completely degraded) and when GRx is equal to GR3, the quality score is 10 (i.e., fully intact).
The computed quality score can be a decimal number. For example, a quality score of 7.5 indicates that 75% of the sample contains large and/or structured RNA (e.g., intact RNA) and 25% of the sample contains small RNA (e.g., degraded RNA).
In certain embodiments, the FRET (Forster Resonance Energy Transfer) response, the non-radiative transfer of excitation energy from one of the dye-RNA complexes to another of the dye-RNA complexes, is also included in the calculations of RNA quality. This FRET complex is excited at about 500 nm and emits at about 666 nm, as distinct from the individual emission of either of the dye-RNA complexes alone. This emission channel, separate from either of the dye-RNA complex emissions alone, is mathematically combined with the other two emission channels for a refinement of the RNA quality metric. Inclusion of this third signal enables samples to be assessed in a three dimensional space, improving the specificity of the quality assessment. In some instances, dependent on fluorometer configuration, the signal from the FRET response is physically combined with one of the other emitted signals from the individual nucleic acid dyes, such as that which is excited at 500 nm and emits at 515 nm, or that which is excited at 648 nm and emits at 666 nm. In these cases the combined signal is then itself mathematically united with the remaining emission channel in such a fashion as to allow an additional refinement of the RNA quality assessment compared to that which is reached through the mathematical combination of the signals individually.
FRET requires two fluorophores to be not only in close proximity (usually ˜10 nm) but to have spectral overlap between the donor's emission and the acceptor's excitation spectra, and an alignment of dipoles of the two fluorophores. It was unexpectedly found that this response could be applied to the IQ assay. This FRET response depends entirely on the relative positions of the two dyes on nearby structures within RNA molecules, such that the signal when excited at 480 nm-500 nm and emission is measured from 640 nm-675 nm has a very interesting dependence on the sample composition. Without wishing to be bound by theory, this response as a function of RNA quality is likely due to some portions of RNA molecules being unraveled upon degradation, with the prevalence of structured fragments being present near the linear fragments decreasing as RNA degrades. The depletion of secondary and tertiary structure and linearization of structured regions of RNA molecules is a hallmark of RNA degradation, whether by environmental factors such as UV-induced chain breaks and basic hydrolysis, or via enzymatic action through ribonucleases. The reduction of tertiary and secondary structure is thus a useful marker of RNA degradation, enabling this FRET response as an indicator of RNA quality.
In situations where high amounts of large and/or structured RNA is present, the RNA IQ Scores as determined by Formula (I) and/or Formula (II) are asymptotic at the high-end of the curve thereby reducing the sensitivity of the RNA IQ Score (
In certain embodiments, the addition of a denaturing agent, such as but not limited to MgCl2, to the assay results in a more linear curve at higher concentrations of large and/or structured RNA and modifies the calculation of the RNA IQ Score wherein the ratio of the small RNA (e.g., the green channel) to the large and/or structured RNA (e.g., the red channel) is calculated using a random forest model with regression. In this embodiment of the RNA IQ Score calculation, the output is the same as the embodiments of the RNA IQ Score calculations described herein above, for example, wherein a value of 3 corresponds to 30% large and/or structured RNA, a value of 7 corresponds to 70% large and/or structured RNA, etc.
The advantages of the methods of determining the integrity and/or quality of RNA of the present disclosure are as follows: 1) able to assess RNA degradation in real-time; 2) simultaneous measurement of large and small RNA, alternatively the measurements can be done sequentially; 3) less sample manipulation than methods currently used; 4) significantly lower cost than microfluidics-based methods, such as the 2100 Bioanalyzer; 5) ability to analyze single samples or multiple samples; 6) ability to measure as little as 1 μl of sample with ≤20% CV (see
It was unexpectedly discovered that the ratio of two dyes that demonstrate selective binding for a particular type of RNA (large vs small), but not specific for either type, resulted in a highly reliable and easily interpretable calculation of RNA integrity that is independent of sample type, concentration, or method of preparation. Currently known methods that are considered to have a higher level of reliability regarding RNA quality use microfluidics and sophisticated algorithms that analyze the content of the entire electrophoretic trace in order to obtain a determination regarding the RNA quality. Methods that do not use such detailed analysis, such as determination of the 28S:18S ratio, are considered to yield less reliable information. Thus, the current state of the art actually teaches away from the development of a method that measures only two variables, such as the RNA quality and integrity methods of the present teachings. However, the present disclosure clearly demonstrates that the method and quality score of Formula (I) and Formula (II) of the current teachings provide reliable and accurate determinations of the integrity and/or quality of the RNA in the sample.
Nucleic Acid Binding Dyes:
The methods of the present disclosure use at least two detectably distinct nucleic acid binding dyes. In certain embodiments, the first nucleic acid binding dye and second nucleic acid binding dye are each independently a cyanine, a xanthene, a coumarin, a pyrene, an indole, a benzofuran, a borapolyazaindacene, a merocyanine, a benzocyanine or a benzopyrilium. In certain preferred embodiments, the first nucleic acid binding dye and the second nucleic acid binding dye are each a cyanine that are detectably distinct from each other.
In the methods described herein, the first nucleic acid binding dye preferentially binds small RNA, and can also bind double-stranded DNA (dsDNA), and the second nucleic acid binding dye preferentially binds large and/or structured RNA.
First Nucleic Acid Binding Dye:
In certain embodiments, the first nucleic acid binding dye exhibits enhanced fluorescence when bound to small RNA such as siRNA or small fragments of RNA. In certain embodiments, the first nucleic acid binding dye is an unsymmetrical cyanine dye including, but not limited to, any compound described in U.S. Pat. Nos. 4,957,870; 4,883,867; 5,436,134; 5,658,751; 5,534,416; 5,863,753; and International Publication No. WO 2014/089421. In certain embodiments, the first nucleic acid binding dye has the structure of Formula (III). In certain preferred embodiments, the first nucleic acid binding dye exhibits a fluorescence enhancement signal that is about 30% greater than the fluorescence signal of Compound 16 at 500 ng/ml siRNA (see WO 2014/089421 for description of determination of fluorescence enhancement). In preferred embodiments, the first nucleic acid binding dye is selected from any of the compounds listed in Table 1 below. In certain preferred embodiments, the first nucleic acid binding dye is Compound 16, Compound 20, Compound 26, Compound 27, Compound 32, Compound 33, Compound 48, Compound 49, Compound 50, Compound 55, Compound 56, Compound 62, Compound 63 or Compound 64 (See Table 1).
In certain embodiments, the first nucleic acid binding dye has the structure of Formula (III):
The water-soluble group can include a polymer (e.g., a polyalkylene oxide, carbohydrate and polypeptide). In certain embodiments, the water-soluble group comprises a polyethylene oxide. In certain embodiments, R4 is a TAIL; R2 is a substituted or unsubstituted phenyl; and/or at least one of R5, R6, R7 and R8 is —OR11, —SR11, or —NR9R11). In certain embodiments, n is 0. In certain embodiments, at least one of R5, R6, R7 and R8 is —OR11. In certain embodiments, OR11 is —OCH3. In certain embodiments, R7 is —OCH3. In certain embodiments, R1 is an unsubstituted alkyl and R10 is H. In certain embodiments, R1 is methyl and R10 is H.
When CAP is —N+R21R22R23 Ψ−, the biologically compatible counter ion Ψ− balances the positive charge present on the CAP nitrogen, which is a quaternary ammonium salt. As used herein, a substance that is biologically compatible is not toxic as used, and does not have a substantially deleterious effect on biomolecules. Examples of Ψ− include, among others, chloride, bromide, iodide, sulfate, alkanesulfonate, arylsulfonate, phosphate, perchlorate, tetrafluoroboronate, tetraarylboride, nitrate, and anions of aromatic or aliphatic carboxylic acids. Preferred Ψ-counterions are bromide, chloride, iodide, perchlorate, and various sulfonates.
In certain embodiments, wherein if p is 0, R1 and R10, which can be the same or different, are independently H, or a substituted or unsubstituted alkyl group, wherein the substitution on the alkyl group, if present, is a carboxyl or (alkyl)ammonium group. In other embodiments, wherein if p is not 0, R1 and R10, which can be the same or different, are independently a substituted or unsubstituted alkyl group, wherein the substitution on the alkyl group, if present, is a carboxyl or (alkyl)ammonium group.
In a preferred embodiment, the first nucleic acid binding dye of Formula (III) is selected from the compounds in Table 1.
Second Nucleic Acid Binding Dye:
In certain embodiments, the second nucleic acid binding dye typically exhibits a fluorescence enhancement when non-covalently associated with a nucleic acid; specifically the fluorescence enhancement is greater when the nucleic acid is RNA than when the nucleic acid is DNA. In certain embodiments, the second nucleic acid binding dye comprises a substituted methine bridge. In certain embodiments, the second nucleic acid binding dye is an unsymmetrical cyanine dye including, but not limited to, any compound described in U.S. Pat. Nos. 4,957,870; 4,883,867; 5,436,134; 5,658,751; 5,534,416; 5,863,753; 7,776,529; 8,470,529; 9,040,561 and 9,403,985. In certain embodiments, the second nucleic acid binding dye has the structure of Formula (IV). In certain preferred embodiments, the second nucleic acid binding dye exhibits a fluorescence enhancement ratio of RNA/DNA of ≥7 (See, U.S. Pat. No. 8,470,529 for a description of the determination of the RNA/DNA fluorescence enhancement ratio). In certain preferred embodiments, the second nucleic acid binding dye exhibits a fluorescence enhancement ratio of RNA/DNA of ≥10. In certain preferred embodiments, the second nucleic acid binding dye exhibits a fluorescence enhancement ratio of RNA/DNA of ≥20. In certain preferred embodiments, the first nucleic acid binding dye is Compound 1, Compound 2, Compound 3, Compound 4, Compound 7, Compound 9, Compound 10, Compound 12, Compound 13, Compound 14 or Compound 15 (See Table 2).
In certain embodiments, the second nucleic acid binding dye has the structure of Formula (IV):
In an exemplary embodiment of the second nucleic acid binding dye of Formula (IV), at least one of R3, R4, and R5 is a substituted alkyl, a substituted 5-, 6- or 7-membered heterocycloalkyl, a substituted 5-, 6- or 7-membered cycloalkyl, a substituted 5-, 6- or 7-membered heteroaryl, or a substituted 5-, 6- or 7-membered aryl that is substituted by an alkyl, —(CH2)k—NR6R7; —COORS, NO2, or halogen, wherein k is an integer from 0 to about 6. The substituents R6, R7 and R8 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, sulfoalkyl or aminoalkyl. In one aspect at least one of R3 and R4 is a thiophenyl, substituted thiophenyl, adamantyl, substituted adamantly, phenyl, substituted phenyl, alkyl, substituted alkyl, benzyl or substituted benzyl.
In an exemplary embodiment of the second nucleic acid binding dye of Formula (IV), the R1 substituent is independently hydrogen, carboxy, sulfo, phosphate, phosphonate, amino, hydroxyl, trifluoromethyl, halogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, aminoalkyl, substituted aminoalkyl, fused benzene, substituted fused benzene, reactive group, solid support or carrier molecule and t is an integer from 1 to 4. In one aspect R1 is alkoxy or halogen. In another aspect R1 is methoxy, Br, Cl, or F.
In an exemplary embodiment, the R2 substituent is an alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, alkoxy, substituted alkoxy, carboxy, carboxyalkyl, hydroxy, hydroxyalkyl, sulfo, sulfoalkyl, amino, aminoalkyl, alkylamino, dialkylamino, or trialkylammonium. In one aspect R2 is methyl, ethyl, propyl, or —(CH2)3SO3−.
In an exemplary embodiment, D has the formula:
wherein R11 is hydrogen, substituted alkyl, unsubstituted alkyl, substituted heteroalkyl, unsubstituted heteroalkyl, substituted aryl, unsubstituted aryl, substituted arylalkyl, unsubstituted arylalkyl, substituted heteroarylalkyl; unsubstituted heteroarylalkyl, substituted heteroaryl, unsubstituted heteroaryl substituted cycloalkyl, unsubstituted cycloalkyl, substituted heterocycloalkyl, unsubstituted heterocycloalkyl, halogen, alkoxy, substituted alkylamino, unsubstituted alkylamino, substituted alkylthio, unsubstituted alkylthio, reactive group, solid support, or carrier molecule and R12 is an alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, alkoxy, substituted alkoxy, carboxy, carboxyalkyl, hydroxy, hydroxyalkyl, sulfo, sulfoalkyl, amino, aminoalkyl, alkylamino, dialkylamino, or trialkylammonium. Alternatively, R11 in combination with an adjacent R11 or R12, together with the atoms to which they are joined, form a ring which is a 5-, 6- or 7-membered heterocycloalkyl, a substituted 5-, 6- or 7-membered heterocycloalkyl, a 5-, 6- or 7-membered cycloalkyl, a substituted 5-, 6- or 7-membered cycloalkyl, a 5-, 6- or 7-membered heteroaryl, a substituted 5-, 6- or 7-membered heteroaryl, a 5-, 6- or 7-membered aryl or a substituted 5-, 6- or 7-membered aryl.
In a preferred embodiment, the second nucleic acid binding dye of Formula (IV) is selected from the compounds in Table 2 below.
1Complex with nucleic acid.
2The ratio of the fluorescence enhancement of the compound when associated with RNA to the fluorescence enhancement of the compound when associated with DNA, as described in U.S. Pat. No. 8,470,529.
Instruments:
Devices for measuring the quality of RNA in a sample are described herein. Devices that can be used in the methods of the present disclosure include fluorometers, including but not limited to those described in U.S. Pat. No. 8,623,282, and microplate readers. Preferred instruments can run a single sample or multiple samples.
In a preferred embodiment, the methods of the present disclosure are performed on a QUBIT™ Fluorometer (Thermo Fisher Scientific, Waltham, MA). In certain preferred embodiments, the QUBIT™ fluorometer enables measurement of samples containing two dyes and enables measurements of samples for assays with high relative fluorescence units (RFUs). The methods described herein can be performed on the QUBIT™ fluorometer in less than 5 seconds per sample with high levels of accuracy using only 1 to 20 μl of sample, even when the sample is very dilute. The schematic shown in
Kits:
In another aspect, kits are provided comprising a dye solution comprising a first nucleic acid binding dye that selectively binds small RNA and a second nucleic acid binding dye that selectively binds large RNA. In certain embodiments, the first nucleic acid binding dye is a compound according to Formula (III) and the second nucleic acid binding dye is a compound according to Formula (IV). In certain preferred embodiments, the first nucleic acid binding dye is selected from the compounds listed in Table 1 and the second nucleic acid binding dye is selected from the compounds listed in Table 2. In certain more preferred embodiments, the first nucleic acid binding dye is Compound 16, Compound 17, Compound 23, Compound 24, Compound 29, Compound 30, Compound 45, Compound 46, Compound 47, Compound 52, Compound 53, Compound 59, Compound 60 or Compound 61. In certain more preferred embodiments, the second nucleic acid binding dye is Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14 or Compound 15. In certain preferred embodiments, the first nucleic acid binding dye is Compound 16, Compound 17, Compound 23, Compound 24, Compound 29, Compound 30, Compound 45, Compound 46, Compound 47, Compound 52, Compound 53, Compound 59, Compound 60 or Compound 61, and the second nucleic acid binding dye is Compound 1, Compound 2, Compound 3, Compound 4, Compound 7, Compound 9, Compound 10, Compound 12, Compound 13, Compound 14 or Compound 15. In certain embodiments, the kits further comprise instructions for use according to any of the methods provided herein. In certain embodiments, the kits further comprise one or more standards selected from a blank standard, a large and/or structured RNA standard, and a small RNA standard. Kits may include reagents useful to conduct the assay methods described herein. In some embodiments, kits comprise at least one of an organic solvent and a desiccant. In certain embodiments, the kits further comprise an assay buffer. In certain embodiments the kits further comprise one or more components that can melt or denature RNA secondary or tertiary structure and/or modify the binding of one or more of the nucleic acid binding dyes. These modifying components include, but are not limited to NaCl, MgCl2, CaCl2, ZnCl2, ammonium acetate, sodium acetate, EDTA, ethanol, SDS, phenol, bovine serum albumin (BSA), guanidine HCl, formamide, urea, thiourea, guanidine isothiocyanate betaine, ethylene glycol and 1,2-propylene glycol.
In certain embodiments, kits are provided comprising:
In certain embodiments, kits are provided comprising:
In certain embodiments, the kits further comprise:
In another aspect, a staining solution is provided comprising a first nucleic acid binding dye, a buffer and optionally, an organic solvent. In some embodiments, the solvent is DMSO.
In certain embodiments of the present disclosure, an RNA quality staining solution is provided, comprising:
The method described in this example provides a faster, easier measurement of the “integrity and quality” (IQ) of RNA samples and is described schematically in
The nucleic acid binding dye that is selective for large and/or structured RNA responds only to large, intact RNA whereas the nucleic acid binding dye that is selective for small RNA responds to single-stranded RNA, but minimally to large RNA. By measuring the ratio of green emission (small RNA) and red emission (large RNA), and the equation of Formula (II), a solution-based assay derived quality score was obtained:
wherein GR2 represents the green/red ratio of Standard 2; GR3 represents the green/red ratio of Standard 3; and GRx represents the green/red ratio of the sample. When GRx is equal to GR2, the quality score is 0 (i.e., completely degraded) and when GRx is equal to GR3, the quality score is 10 (i.e., fully intact).
The readout shown in
A series of solutions were prepared of rRNA and siRNA such the final concentrations of nucleic acids were as follows in 1×TE buffer (either siRNA or rRNA): 0 ng/μL, 0.5 ng/μL, 1.0 ng/μL, 2.0 ng/μL, 4.0 ng/μL, 6.0 ng/μL, 8.0 ng/μL, and 10.0 ng/μL.
An assay solution was then made by 200× dilution of a DMSO solution comprised of the following in 1× TE buffer with 0.01% CHAPS: DMSO Stock: 0.2 mg/mL Compound 16, 0.0047 mg/mL Compound 15.
Each sample was diluted 20× with assay buffer by adding 10 μL sample to 190 μL assay solution in triplicate in a 96-well plate. The sample and assay solution combination was then incubated for 2 minutes, then assayed on a Tecan Infinite® m1000 Pro plate reader (Tecan Trading AG, Switzerland), using the following settings:
As shown in
A series of solutions were prepared containing both rRNA and siRNA such the final concentrations of nucleic acids were as follows in 1× TE buffer: 0 ng/μL, 0.5 ng/μL, 1.0 ng/μL, 2.0 ng/μL, 4.0 ng/μL, 6.0 ng/μL, 8.0 ng/μL, and 10.0 ng/4 (see Table 3 below).
An assay solution was then made by 200× dilution of a DMSO solution comprised of the following in 1× TE buffer with 0.01% CHAPS: DMSO Stock: 0.2 mg/mL Compound 16, 0.047 mg/mL Compound 15.
Each sample was diluted 20× with assay buffer by adding 10 μL sample to 190 μL assay solution in triplicate in a 96-well plate. The sample and assay solution combination was then incubated for 2 minutes, then assayed on a Tecan Infinite® m1000 Pro plate reader, using the following settings:
The RFUs collected at 644/673 and 500/525 were then plotted against the concentration of total nucleic acid in the original sample (
A series of samples were prepared, with varying concentrations of rRNA and siRNA in 1× TE buffer, with the following compositions (see Table 4 below):
An assay solution was then made by 200× dilution of a DMSO solution comprised of the following in 1×TE buffer with 0.01% CHAPS: DMSO Stock: 0.2 mg/mL Compound 16, 0.047 mg/mL Compound 15.
Each sample was diluted 20×with assay buffer by adding 104 sample to 1904 assay solution in triplicate in a 96-well plate. The sample and assay solution combination was then incubated for 2 minutes and assayed on a Tecan Infinite® m1000 Pro plate reader, using the following settings:
The RFUs collected at 644/673 and 500/525 were then plotted against the concentration of each type of nucleic acid in the original sample. The 500/525 channel does increase significantly as a function of siRNA concentration, as expected (
By a simple manipulation of the data from the aforementioned experiment using the equation of Formula (I), the ratio of emissions from the channels 500/525 and 644/673 can be mapped onto a quality score, such that higher numbers imply smaller amounts of small RNA in the sample, and thus less degradation (
By dividing the ratio of the fluorescence emission signal of the first nucleic acid binding dye (in this embodiment, the green emission channel) to the fluorescence emission signal of the second nucleic acid binding dye (in this embodiment, the red channel), herein termed the Green/Red Ratio or “G/R ratio” by a constant to scale it to 10, and subtracting it from 10 to reverse the slope, the ratio becomes a scale from 10 to 0, with 10 representing 100% intact rRNA and 0 representing 100% degraded RNA (see
An assay solution was made by 200× dilution of a DMSO solution comprised of the following in 1× TE buffer with 0.01% CHAPS: DMSO Stock: 0.2 mg/mL Compound 16, 0.047 mg/mL Compound 15.
250 μL of a sample containing 100 ng/μL rRNA was diluted 20×with assay solution, and this solution was distributed to 21 wells in a 96 well plate such that each well contained 2004 of solution. To each of these solutions was then added volumes of a stock solution containing RNase A, such that the following final concentrations were reached, in triplicate: 0 fM RNase A, 50 fM RNase A, 100 fM RNase A, 250 fM RNase A, 500 fM RNase A, 750 fM RNase A, and 1000 fM RNase A.
These solutions were then measured on a Tecan Infinite m1000 Pro plate reader at the following timepoints: 0 minutes, 1 minute, 7 minutes, 13 minutes, 18 minutes, 26 minutes, 32 minutes, and 34 minutes.
The RFU at each channel for each timepoint for each solution was then normalized to T=0 minutes, and plotted as a function of time after addition of RNase A (
Plotting the ratio of the 500/525 channel to the 644/673 channel of the above-mentioned experiment, the ratio of the two signals increases as a function of time and thus, of the RNA degradation (
By normalizing the t=0 timepoint of the 644/673 channel to 1, and the t=0 timepoint of the 500/525 channel to 0 from the sample series of the above experiment treated with 50 fM RNase, a plot was obtained of the size profile of the rRNA while it was being digested by RNase A (
To a sample comprised of 100 μL of 500 ng/μL of rRNA was added RNase A such that the final concentration of RNase A was 100 fM. From this solution, 5 μL aliquots were removed from the solution at these defined timepoints: T=0 minutes, 4 minutes, 10 minutes, 13 minutes, 16 minutes, 19 minutes, 21 minutes, 24 minutes, 27 minutes, and 30 minutes.
Immediately upon removal from the reaction solution, each sample was treated with 5 units of RNaseOUT™ Recombinant Ribonuclease Inhibitor in 1 μL water, an inhibitor of RNase activity, and vortexed then spun down. Each sample was then diluted to a final volume of 50 μL with nuclease free water, such that the final concentration was 100 ng/μL RNA. This sample from each timepoint was then assayed via both Agilent 2100 Bioanalyzer using the RNA 6000 Nano kit and via fluorescence using the conditions described below.
An assay solution was then made by 200× dilution of a DMSO solution comprised of the following in 1× TE buffer with 0.01% CHAPS: DMSO Stock: 0.2 mg/mL Compound 16, 0.047 mg/mL Compound 15.
Each sample was diluted 20× with assay buffer by adding 104 sample to 1904 assay solution in triplicate in a 96-well plate. The sample and assay solution combination was then incubated for 2 minutes and assayed on a Tecan Infinite® m1000 Pro plate reader, using the following settings:
The fluorescence from the 500/525 and 644/673 channels were plotted against time after the addition of RNase A, showing the RNA degradation with these two channels (
By plotting the ratio of emission from the 500/525 and 644/673 channels against the time after additions of RNase, the increase of this ratio as a function of RNA degradation can be seen (
The linear relationship between the ratiometric emission measurement and the RIN determined via Bioanalyzer demonstrates a strong correlation (
Over many runs with concentrations of RNase ranging from 100 fM to 1 fM using similar reaction and assay conditions as described above, the RIN and RNA-IQ metrics can be seen to have a strong correlation up to RIN≤8 (
Three solutions of rRNA were prepared at the following concentrations, 1000 ng/μL, 100 ng/μL and 50 ng/μL, via dilution of a 1000 ng/μL stock in nuclease free water. Each solution was then diluted in triplicate with an appropriate dilution scheme such that the final concentration was 5 ng/μL in 200 μL assay solution (volume of sample used, 1 μL for 1000 ng/μL sample, 10 μL for 100 ng/μL sample, and 20 for 50 ng/μL sample). The diluent was comprised of 1×TE with 0.01% CHAPS, containing 0.5% of a DMSO solution containing 0.2 mg/mL Compound 16 and 0.047 mg/mL Compound 15.
Each solution was prepared in this way in triplicate, placed in QUBIT™ tubes, and measured on the QUBIT™ Fluorometer. Even for the sample with only 1 μL used, 4.2% CV was obtained for the green/red ratio (
The nucleic acid binding dye that binds to small RNA can also bind to DNA. This is beneficial because DNA is often a contaminant in RNA samples and can be problematic for almost all downstream applications of RNA analysis. Knowledge of the presence of DNA as a contaminant is indicative of potential issues using the RNA sample for further study.
In the experiment shown in
The RFUs collected at 644/673 and 500/525 were then plotted against the amount of nucleic acid in the sample (
In the experiment shown in
The RFUs collected at 644/673 and 500/525 were then plotted against the amount of nucleic acid in the sample (
Samples were prepared from FFPE preserved clinical tissue samples via the ONCOMINE™ kit protocol (Thermo Fisher Scientific, Waltham, MA). Tissue slides were deparaffinized using xylene and ethanol, then collected and digested with proteinase. The RNA and DNA were separated via filter cartridges, each collected individually. RNA was quantified via fluorometric measurement using the reagents supplied in the ONCOMINE™ kit via plate reader, then subjected to reverse transcription reaction to generate cDNA from the isolated RNA. The purified cDNA was then amplified, labeled, and combined in a library for sequencing. The library was loaded onto ION SPHERE™ particles (Thermo Fisher Scientific, Waltham, MA), then sequenced using the Ion PGM Dx System (Thermo Fisher Scientific, Waltham, MA). Sequencing results for the cDNA samples were then compared to reference sequences to determine the percentage of reads that could be matched to those in the reference sequences. This measure of reads that correspond to the reference sequences were presented as the percent of mappable reads.
RNA isolated from clinical FFPE tissue retains was subjected to RNA Seq on the Ion Torrent ONCOMINE™ platform (described herein above) and compared to RNA IQ results obtained using the method described in Example 1. It was found that sufficiently mapped reads (>50% mappable reads) correlated to RNA IQ>4. With this guideline, only 4 out of 60 samples resulted in a false negative result, a 6.7% failure rate. The results are shown in
To evaluate the effect of additives to the assay buffer on the linearity of the RNA IQ response, an eleven-point titration curve was made by diluting a range of standard 2 with a range of standard 3 such that the total amount of RNA was identical for each of the samples but the percentage of large and/or structured RNA ranged from 0-100%. To each of the samples a dye working solution was added for a total volume of 200 μL. Samples were well mixed by trituration and incubated at room temperature for a minimum of 2 minutes prior to reading on the QUBIT™ fluorometer instrument (Thermo Fisher Scientific, Waltham, MA). The RNA quality IQ Score was determined using the ratio of green to red response according to Formula (II). Results are shown in
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application is a continuation of U.S. application Ser. No. 16/649,088, filed Mar. 19, 2020, which is a 371 National Stage of PCT/US2018/054292, filed Oct. 4, 2018, and claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/568,896, filed Oct. 6, 2017. The entire contents of the aforementioned applications are incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 62568896 | Oct 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16649088 | Mar 2020 | US |
| Child | 18179184 | US |
